Rifampin

CHEMBL374478 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

822.9 g/mol

LogP

4.9

Phase

4

A broad-spectrum antibiotic and a cornerstone of tuberculosis treatment, used in combination regimens to kill Mycobacterium tuberculosis. It works by inhibiting bacterial RNA synthesis and is also used to prevent infections caused by Neisseria meningitidis.

Molecular Weight

822.9000 g/mol

LogP

4.90

TPSA

220.00 Å²

Lipinski RO5

Fail

Therapeutic Areas

Alzheimer's Disease Bladder Cancer Breast Cancer Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Chronic Pain Colorectal Cancer Deep Vein Thrombosis / Pulmonary Embolism Endometriosis Hematology Hepatitis C HIV/AIDS Hypertension Infectious Disease Leukemia Lymphoma Malaria Melanoma Multiple Sclerosis Non-Alcoholic Fatty Liver Disease Non-Small Cell Lung Cancer Obesity Oncology Ovarian Cancer Pain Management Pancreatic Cancer Parkinson's Disease Prostate Cancer Rheumatoid Arthritis Thyroid Cancer Tuberculosis Type 2 Diabetes

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C

InChI

InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1

Molecular Formula

C43H58N4O12

HBD / HBA

6 / 15

Rotatable Bonds

5

Heavy Atoms

59

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A broad-spectrum antibiotic and a cornerstone of tuberculosis treatment, used in combination regimens to kill Mycobacterium tuberculosis. It works by inhibiting bacterial RNA synthesis and is also used to prevent infections caused by Neisseria meningitidis.

Yes, Rifampin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL374478. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 135398735. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Looking for patient-friendly information?

Rifampin on PillFYI

Structure

Quick Data

Formula: C43H58N4O12
Synonyms: 1

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.